Loading...

World-Class Retina Care. Community-Based Caring.

Texas Retina Honors Founder Dr. Vaiser with Donation to Retina Foundation

Posted On August 21, 2024 / By / Posted in Blog

Texas Retina Honors Founder Dr. Vaiser with Donation to Retina Foundation

On behalf of the entire Texas Retina team, Gary Edd Fish, MD, recently presented a $2,000 donation to the Retina Foundation to honor the 90th birthday of one of Texas Retina’s founders,

read more
Posted On August 15, 2024 / By / Posted in Blog

Dr. Abbey Publishes Case Report on Management of Cystoid Macular Edema in Coats’ Disease

Texas Retina’s Ashkan M. Abbey, MD, recently co-authored a case report in the medical journal Ophthalmic Surgery, Lasers and Imaging Retina (OSLI Retina) on the use of an injectable flucocinolone implant for

read more
Posted On August 13, 2024 / By / Posted in Blog

Can Ozempic Affect Your Eyes or Vision?

Initially approved by the U.S. Food and Drug Administration (FDA) to help control blood sugar and treat type 2 diabetes, semaglutide (brand names Ozempic, Wegovy and Rybelsus) has also emerged as a

read more
Posted On August 12, 2024 / By / Posted in Blog

Dr. Wang Invited to Serve as Guest Lecturer at Ohio State University

Texas Retina’s Robert C. Wang will speak at The Ohio State University’s 7th Annual Retina Case Forum on Friday, August 16, 2024, as an invited guest lecturer. The event is a case-based

read more
Posted On August 6, 2024 / By / Posted in Blog

Recent Study Published in Journal of Clinical Oncology Highlights Importance of Prognostic Biomarker for Uveal Melanoma

The results of the Collaborative Ocular Oncology Study Number 2 (COOG2) were published in the July 2024 issue of the Journal of Clinical Oncology and validated the prognostic accuracy of the integrated

read more
Posted On August 5, 2024 / By / Posted in Blog

Dr. Kothari Featured in New Retina Radio Podcast

The New Retina Radio Journal Club and Vit-Buckle Society recently released a podcast featuring Texas Retina’s Nikisha Kothari, MD. In it, she discusses recent research findings from the Diabetic Retinopathy Clinical Research

read more
Posted On August 2, 2024 / By / Posted in Blog

Dr. Abbey First in the World to Administer Novel Trispecific Fusion Antibody EB-105 for Diabetic Macular Edema as Part of Phase Ib LOTUS Clinical Trial

On July 9, Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, dosed the first patient in the Phase Ib LOTUS trial of EB-105, the world’s first pentavalent trispecific

read more
Posted On July 30, 2024 / By / Posted in Blog

Dr. Anand Presented Interim Study Results of New Gene Therapy for X-linked Retinitis Pigmentosa at ASRS 2024 Annual Meeting

Texas Retina’s Rajiv Anand, MD, presented “Subretinal AGTC-501 Gene Therapy for XLRP: 12-Month Interim Safety & Efficacy Results of the Randomized Controlled Multicenter Phase II Skyline Trial” at the 2024 Annual Meeting

read more
Posted On July 25, 2024 / By / Posted in Blog

Dr. Wang Presented Initial Study Results of New Non-infectious Uveitis Treatment at ASRS 2024 Annual Meeting

Texas Retina’s Robert C. Wang, MD, presented “Safety and Efficacy of Brepocitinib, a TYK2/JAK1 Inhibitor, in Active Non-Infectious Uveitis: 24-Week Results from a 52-Week Phase II Study (NEPTUNE)” at the 2024 Annual

read more
Posted On July 24, 2024 / By / Posted in Blog

Dr. Abbey Presented Real-world Outcomes of Fluocinolone Acetonide Intravitreal Implant for Non-infectious Uveitis at ASRS 2024 Annual Meeting

Texas Retina’s Ashkan M. Abbey, MD, presented “36-month Optical Coherence Tomography Outcomes from CALM: A Registry Evaluating Treatment of Chronic Non-infectious Uveitis with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant” at the

read more